Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02750059
Other study ID # SEARCH 018
Secondary ID 1R01NS084911-01
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2015
Est. completion date February 2018

Study information

Verified date September 2019
Source South East Asia Research Collaboration with Hawaii
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To compare telmisartan therapy + antiretroviral therapy (ART) versus ART alone during acute Human Immunodeficiency Virus (HIV)a infection in reducing systemic immune activation and trafficking of activated and HIV-infected cells to the central nervous system (CNS), and limiting establishment and persistence of the CNS reservoir of HIV.

At 48 weeks (during the telmisartan therapy) and 72 weeks (~6 months after cessation of telmisartan augmentation), the investigator expect subjects in the telmisartan group will have reduced levels of blood and CSF immune activation markers, reduced brain inflammation, lower CSF HIV ribonecleic acid (RNA) and improved neuropsychological testing performance.

Secondary objective: In subjects who are willing to undergo the optional inguinal lymph node biopsy, the study will determine whether subjects receiving telmisartan plus ART for 48 weeks develop less lymphoid tissue fibrosis than subjects receiving ART alone for 48 weeks.

Subject population: Male and female subjects age ≥ 18 years old with acute HIV infection who are identified and enrolled in SEARCH 010/RV254 protocol will be asked to co-enroll in this study.

Number of subjects: 21

Duration of follow-up: 72 weeks

Study design: 21 acutely HIV-infected subjects will be randomized 2:1 to treatment with telmisartan + ART (n=14) vs. ART alone (n=7) for the first 48 weeks followed by ART alone in both arms to week 72. Blood and CSF, magnetic resonance imaging (MRI), and neuropsychological testing and exam will be collected at baseline, week 48 and week 72. Inguinal lymph node biopsy is an optional procedure that will be offered at baseline and week 48.


Description:

Clinical assessments:

Neurological exam: South East Asia Research Collaboration with Hawaii (SEARCH) employs the AIDS Clinical Trials Group (ACTG)-derived HIV macroneurological examination, a physician rated symptoms assessment of cognitive features typical of HAND and peripheral neuropathy

Neuropsychological assessments: SEARCH employs the HIV neurocognitive battery originally developed by Maj et al. designed to minimize cultural bias and tested in Bangkok. All subjects will have the full SEARCH battery as previously published, avoiding evaluations following invasive procedures.

Quantification of Drug use: Drug and alcohol use are assessed with a structured interview including methamphetamine, heroin, and marijuana based on a Thai Red Cross study defining frequently abused drugs in Bangkok. Urine is stored at each visit and may be later tested for illicit drugs. Evidence of intoxication is documented so that neuropsychological data can be censored.

Lumbar punctures are completed per standard clinical procedures using a Sprotte® (pencil-point) needle to minimize complications. Standard assessments of CSF and serum, protein and cell count are completed and approximately 20cc are collected and ultra-centrifuged, Cell pellets of both blood and CSF will be cryopreserved for future potential studies, with subject consent. Supernatants are divided into 0.5cc aliquots, and frozen to -80oC on the same day. Venereal Disease Research Laboratory test (VDRL)/Rapid Plasma Reagin (RPR) will be assessed at baseline and in follow up if risk for new syphilis exposure is reported. Participant hospitalization for hydration will be completed, if needed. Participants will be compensated for their time based on Institutional Review Board (IRB)-approved rates.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date February 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age = 18 years old

2. Have protocol-defined acute HIV-1 infection (Tested 4th generation HIV enzyme immunoassay [EIA] negative and NAT positive or tested 4th generation HIV EIA positive, negative by less sensitive EIA and nucleic acid testing [NAT] positive)

3. Be part of the SEARCH 010/RV 254 study

4. Ability and willingness to start ART immediately after diagnosis

5. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a member of the study staff and may then give informed consent by using making a thumb print

6. Availability for follow-up for the duration of the planned study

7. Systolic blood pressure = 110 mmHg

8. Agree to undergo lumbar puncture at weeks 0, 48 and 72

9. Ability and willingness to provide informed consent

Exclusion Criteria:

1. Pregnancy (current or within the last 6 months) or breastfeeding

2. Uncontrolled hypertension

3. Use of thiazolidinediones or other angiotensin receptor blockers class [losartan, irbesartan, olmesartan, valsartan, candesartan (washout permitted)]

4. Screening laboratory values: absolute neutrophil count (ANC) < 750 cells/mm3, hemoglobin <10 gm/dL creatinine clearance<30mL/min (estimated by the Cockcroft-Gault equation using ideal body weight)

5. Known renal artery stenosis

6. Known cirrhosis or severe liver disease

7. Unstable coronary artery disease/angina or decompensated congestive heart failure

8. Any history of intolerance to any angiotensin II receptor blocker (ARB)

9. Need for ongoing potassium supplementation

10. Any contraindication to lumbar puncture such as history of bleeding diathesis or known cerebral mass lesion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TDF/3TC/EFV + Telmisartan
The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
TDF/3TC/EFV only
Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.

Locations

Country Name City State
Thailand SEARCH Thailand Bangkok

Sponsors (2)

Lead Sponsor Collaborator
South East Asia Research Collaboration with Hawaii National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference between study arms at weeks 48 and 72 in CSF neopterin 48 and 72 weeks
Secondary Difference between study arms in lymphoid tissue fibrosis at week 48 48 weeks
Secondary Difference between study arms at weeks 48 and 72 in brain inflammation by magnetic resonance spectroscopy (MRS) 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in CSF HIV RNA by single copy assay 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in aggregate neuropsychological testing performance score (NPZ-4) on Grooved Pegboard, Color Trails 1, Color Trails 2 and Trail Making A 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in CSF monocyte chemoattractant protein-1 (MCP-1) levels 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in CSF interferon-gamma-inducible protein-10 (IP-10) levels 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in plasma neopterin levels 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in plasma soluable CD14 (sCD14) levels 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in plasma interleukin-6 (IL-6) levels 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in plasma D-dimer levels 48 and 72 weeks
Secondary Difference between study arms at weeks 48 and 72 in plasma soluable CD163 (sCD163) levels 48 and 72 weeks
See also
  Status Clinical Trial Phase
Completed NCT02384395 - Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection N/A
Completed NCT00734344 - Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection N/A
Completed NCT01434706 - Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection N/A
Active, not recruiting NCT03711253 - Empiric Treatment for Acute HIV in the ED Phase 4
Completed NCT01154673 - Intense Acute Infection Study Phase 2/Phase 3
Terminated NCT00855413 - HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine Phase 4
Completed NCT02467439 - Acute Partner and Social Contact Referral: iKnow N/A
Not yet recruiting NCT05719441 - A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission Phase 2
Completed NCT03579381 - Specimen Repository for HIV Immunopathogenesis
Completed NCT01369056 - HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence N/A
Completed NCT02170246 - Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection Phase 1
Completed NCT02475915 - Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection Phase 1/Phase 2
Completed NCT02470351 - Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS N/A
Completed NCT00924898 - Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) Phase 4
Completed NCT02614950 - Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection N/A
Completed NCT01197027 - Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection Phase 3
Active, not recruiting NCT02231281 - Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults Phase 3
Recruiting NCT05728996 - Netherlands Cohort Study on Acute HIV Infection
Recruiting NCT00796146 - Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
Recruiting NCT00796263 - Antiretroviral Therapy for Acute and Chronic HIV Infection Phase 3